CClinicalTrials.gg
CompletedNCT00376233Updated Oct 12, 2006

Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia

An observational study in Schizophrenia and Cannabis Abuse, sponsored by University of Jena. Completed at 1 site in Germany. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-10-12.

Sponsored by University of Jena · Observational

Study type
Observational
Model
Defined population
Time perspective
Other
Enrollment
100
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Increasing evidence suggests modulating effects of cannabinoids on time of onset, severity, and outcome of schizophrenia. Efforts to discover the underlying pathomechanism have led to the assumption of gene x environment interactions including premorbid genetical vulnerability and worsening effects of continuing cannabis use. For a main characteristic of psychoactive delta-9-tetrahydrocannabinol is its affinity to biological membranes, which are known to be disturbed in schizophrenia patients and genetic high-risk populations.

Here we assess an hypothesised association between premorbid lipid disturbance and metabolic effects of external cannabinoids in schizophrenia.

Intensity of niacin (methylnicotinate) skin flushing, indicating disturbed prostaglandin-mediated processes, is used as peripheral marker of lipid-arachidonic acid pathways and investigated in cannabis consuming and non-consuming schizophrenia patients and in healthy controls. Methylnicotinate is applied in three concentrations onto the forearm skin. Flush response is assessed in three minute intervals over 15 min using optical reflection spectroscopy.

Read the detailed description

Subjects Niacin skin tests are performed on acutely ill consecutively admitted schizophrenia patients suffering not more than two psychotic episodes. All meet DSM-IV criteria for paranoide schizophrenia. Diagnosis is made by two independent experienced psychiatrists and further supported by structured clinical interview (SCID IV) (Wittchen et al 1997). Majority of patients is treated mostly with atypical neuroleptic drugs. The patient population is subdivided in one group having used cannabis on a regular basis (≥ 0,5 g/d, at least 3 month) prior to admission, and another group having never used cannabis apart from unique trials. Cannabis consuming patients do not use any other drug or alcohol on a regular basis. Psychiatric symptoms are assessed using Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962), Scale of Assessment of Positive Symptoms (SAPS) (Andreasen 1984), Scale of Assessment of Negative Symptoms (SANS) (Andreasen 1983), and Symptom Check List 1990 Revised (SCL 90-R) (Kaplan et al 1998).

Patients are compared to healthy volunteers recruited by newspaper advertisement including again one group of cannabis users (duration and dose of cannabis use as in patients) and one group without any cannabis experience. Controls are interviewed in-depth to rule out a current psychiatric diagnosis or psychiatric personal or family history. As in patients, SCL 90-R is also applied in controls.

All cannabis-using participants are tested positive for cannabinoids in urine at the time of niacin testing. Subjects with any current or history of skin disorders (eczema, atopical dermatitis, psoriasis) or recent treatment with steroids or non-steroidal antiinflammatory drugs (e.g. acetylsalicylic acid) are excluded from the study before niacin testing. The study is approved by the Ethics Committee of Friedrich-Schiller-University Jena. All participants give written informed consent to participate in the study.

Niacin skin test protocol Methylnicotinate (C7H7NO2, 99%, Sigma-ALDRICH Chemie GmbH, Germany) is applied simultaneously in three dilutions (0.001 M, 0.01 M, 0.1 M) of 50 µl each to the skin at the inner side of the forearm using chambered plaster for epicutaneous testing. After 90 sec the plaster is removed. Skin flushing is quantified before and up to 15 minutes after methylnicotinate exposure in 3-min intervals, starting 90 sec after removal of the methylnicotinate patches. Methylnicotinate solutions are freshly prepared for each test to prevent any influence of sunlight.

Reflection spectroscopy Optical reflection spectroscopy (ORS) is applied as described in more detail by Smesny et al 2001. Skin content of oxygenated blood is assessed with a handheld optical reflection spectrometer (spectral range: 400 nm to 700 nm, area of measurement: diameter 5 mm), using the oxyhemoglobin (HbO2) absorption double peak at 542 nm and 577 nm. Each measurement is repeated three times (within 10 sec) and then averaged.

Spectroscopic data are processed automatically creating difference spectra by subtraction of pre-stimulation reflection intensities (also measured three times) from test intensities. Two Gaussian curves are fitted to the HbO2-absorption double peak. The area under the resulting sum curve is taken as measure of current skin flushing (measured in arbitrary units [a.u.]).

Data analysis We plan to conduct a repeated measure analysis of variance (ANOVA) with TIME (3, 6, 9, 12, 15 min) and methylnicotinate CONCENTRATION (0.001 M, 0.01 M, 0.1 M) as within-subject factors and GROUP (patients, controls) and CANNABIS (cannabis user, cannabis non-user) as between subjects factors. GENDER, and AGE are treated as co-variates. For post-hoc comparison of single values, Mann-Whitney-U-Tests are calculated. Psychopathological ratings of the SCL 90-R are compared between groups using an univariate ANOVA with the same between group factors (GROUP, CANNABIS) and co-variates (AGE, GENDER) as above. Furthermore, effects of cannabis use on SAPS, SANS, and BPRS are investigated within the patient group. In order to explore a possible association between age or psychopathological ratings and skin flushing, Spearman correlation coefficients will be calculated. Due to the high number of calculated coefficients the significance level will be set on p \< 0.01.

02

Conditions studied

  • Schizophrenia
  • Cannabis Abuse

Keywords

  • Schizophrenia,
  • Cannabinoids,
  • Arachidonic Acid,
  • Niacin,
  • Prostaglandins
03

In context

Marijuana Abuse

517 studies on the registry are indexed under Marijuana Abuse; 114 are open to participants now.

This study's enrollment of 100 is close to the median of 100 across 78 observational studies indexed under Marijuana Abuse.

Browse Marijuana Abuse studies →

Lead sponsor

University of Jena is the lead sponsor of 89 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patients:

  • acutely ill
  • consecutively admitted
  • diagnosis of schizophrenia according to DSM-IV criteria for paranoide schizophrenia.
  • not treated or treated with atypical neuroleptic drugs
  • cannabis use on a regular basis (≥ 0,5 g/d, at least 3 month) prior to admission or
  • never use of cannabis apart from unique trials
  • no use of any other drug or alcohol on a regular basis.

Controls:

  • healthy volunteers recruited by newspaper advertisement
  • cannabis user (duration and dose of cannabis use as in patients)or
  • no cannabis experience at all

All cannabis consuming participants:

  • positive for cannabinoids in urine test at the time of niacin testing

Exclusion criteria

Exclusion Criteria:

Controls:

  • current psychiatric diagnosis or psychiatric personal or family history.

All individuals:

  • any current or history of skin disorders (eczema, atopical dermatitis, psoriasis)
  • recent treatment with steroids or non-steroidal antiinflammatory drugs (e.g. acetylsalicylic acid)
05

Study design

Observational model
Defined population
Time perspective
Other
Enrollment
100 participants
06

Study locations

1 site
  • University of Jena, Department of Psychiatry
    Jena, Thueringen D-07743, Germany
07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00376233
Lead sponsor
University of Jena
First posted
Sep 14, 2006
Start date
Feb 2004
Completion
Jun 2005
Last update
Oct 12, 2006

Study contacts

Heinrich Sauer, PhD
study director · University of Jena
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion